GlobeNewswire·Oct 19, 2026, 6:45 AM ET

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

BNTX

BioNTech will present 16 abstracts covering 10 tumor types at the ESMO 2026 Congress in Madrid from October 23–27, 2026.
Late-breaking oral presentation will feature first global Phase 2 data from the ROSETTA Lung-107 trial evaluating pumitamig plus docetaxel in metastatic non-small cell lung cancer patients progressing after prior immunotherapy & chemotherapy.
Global Phase 2 data will be shared for the novel-novel combination of pumitamig & elfetabart drozuntecan (a B7-H3-targeting ADC) in multiple advanced solid tumors.
Subgroup analyses from two Phase 2 trials show systemic & intracranial efficacy of pumitamig plus chemotherapy in small cell lung cancer & triple-negative breast cancer patients with brain metastases.
First results from a Phase 2 trial in China demonstrate encouraging antitumor activity for pumitamig plus FOLFIRI in patients with unresectable neuroendocrine neoplasms after first-line platinum-based chemotherapy.
First results from a global Phase 2 trial indicate encouraging preliminary antitumor activity & manageable safety for pumitamig combined with elfetabart drozuntecan across multiple advanced solid tumor types.
BioNTech is advancing a diversified oncology pipeline including next-generation immunomodulators, antibody-drug conjugates, & mRNA cancer immunotherapies across 13 ongoing Phase 3 trials.
Additional presentations cover pumitamig combinations in renal cell carcinoma, gastric cancer, hepatocellular carcinoma, breast cancer, & prostate cancer, alongside data on gotistobart, BNT317, Beruzatatug pelitecan, & BNT329.